statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes plc Reports Second Quarter 2024 Financial Results

Alkermes plc Reports Second Quarter 2024 Financial Results Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire DUBLIN, July 24, 2024 Second Quarter Revenues of $399.1 Million Net...

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024 Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN, July 17, 2024 DUBLIN, July 17, 2024...

6 Analysts Assess Alkermes: What You Need To Know

Latest Ratings for ALKS
 DateFirmActionFromTo Jan 2022Cantor FitzgeraldUpgradesNeutralOverweight Dec 2021CitigroupInitiates Coverage OnNeutral Nov 2021SVB LeerinkMaintainsMarket Perform
 View...

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 Alkermes Presents Data From Phase 1b Study of ALKS 2680...

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes to Participate in Two Upcoming Investor Conferences Alkermes to Participate in Two Upcoming Investor Conferences PR Newswire DUBLIN, May 29, 2024 DUBLIN, May 29, 2024 /PRNewswire...

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PR Newswire DUBLIN, May 28, 2024 Late-Breaking Abstracts Containing...

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring...

7 Analysts Assess Alkermes: What You Need To Know

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN, May 2, 2024 DUBLIN, May 2, 2024...

Alkermes plc Reports First Quarter 2024 Financial Results

Alkermes plc Reports First Quarter 2024 Financial Results Alkermes plc Reports First Quarter 2024 Financial Results PR Newswire DUBLIN, May 1, 2024 First Quarter Revenues of $350.4 Million GAAP Net...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Volume	2.1M
52-Wk High	$32.88
52-Wk Low	$21.66

ALKS Alkermes plc

About

Feed

News

Sentiment

Earnings

Fundamentals